Rx Advertising: Can Consumers And Doctors Tell When Drug Promos Are Deceptive?
Executive Summary
US FDA to assess whether consumers and healthcare professionals can detect and report false or misleading promotions; Bad Ad program could be expanded to consumers.
You may also be interested in...
Drug Promotion: Consumers Prefer Live Action Over Animated Characters In TV Ads
US FDA research finds consumer attitudes are more positive when animated characters personify drug benefits or sufferers, rather than representing the disease itself; OPDP staff also present research on consumer understanding of oncology endpoints and prescribers’ ability to detect deceptive ads.
Identifying Deceptive Rx Advertising: FDA Rejects PhRMA's Criticisms Of Its Study
US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.